NCT06976697招募中不适用
Safety And Efficacy of Remotely Supervised Home-Based tDCS Treatment Of Major Depressive Disorder
Sooma Medical Inc1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2025年6月27日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- MADRS: change from baseline
研究概览
简要总结
The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.
详细描述
The study stages include: screening, eligibility evaluation, randomization to active or sham arm (1:1), the first treatment period (weeks 1-10) with sham-control and the optional open-label phase (weeks 11-20) where all treatments will be in active mode.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 22 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria:
- •22 - 70 years of age
- •Diagnosis of Unipolar MDD (DSM-V)
- •PHQ-9 score of ≥12 AND MADRS score of ≥ 20 at baseline
- •Antidepressant medication ongoing
- •If in psychotherapy, have maintained stable psychotherapy
- •Have access to a smartphone or other device running Android 7.0+ or iPhone Operating System (iOS) 13+
- •Be under the care of a psychiatrist or a primary care physician
- •Allow communication between the investigators/study staff and any healthcare provider who currently provides and/or has provided service to the patient/subject within at least two years
- •Provide the name and contact of at least two adult persons who reside within a 60-minute drive of the patient's residence.
- •Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study
- •Be willing and able to comply with all study procedures
- •Agree to meet all of the inclusion criteria throughout their participation in the study. Otherwise, the subject will be discontinued from the study
- •Be able to understand, speak, and read English sufficient for the completion of trial assessments
排除标准
- •Current state of mania or psychosis, or have a history of mania or psychosis.
- •Treatment resistant depression.
- •Are diagnosed with vitamin or hormonal deficiencies that may mimic mood disorders, as determined by the investigator.
- •Be currently receiving any other interventional therapy for MDD other than a stable regimen of antidepressants or psychotherapy as defined in the inclusion criteria or have a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), or other brain stimulation.
- •Have moderate or greater suicidality risk, or an attempt of suicide during lifetime or any previous hospitalization for suicidal behavior.
- •Diagnosis of sleep apnea with prescribed treatment (unless they are on CPAP treatment and are compliant with treatment) or a diagnosis of insomnia that is unrelated to depression, as determined by the investigator.
- •Have any structural lesion or any neurocranial defect or any other clinically significant abnormality that might affect safety, study participation, or confound interpretation of study results, as determined by the investigator.
- •Have any implant in the brain (e.g., DBS) or neurocranium, or any other active implantable medical device anywhere in the body (e.g. pacemaker, insulin pump).
- •Have a history of epilepsy or seizures.
- •Have shrapnel or any ferromagnetic material in the head.
- •Have any disorder that would impair the ability to complete the study questionnaires.
- •Have been diagnosed with autism spectrum disorder.
- •Have an alcohol use disorder or substance use disorder (past 12 months).
- •Have a cognitive impairment (including dementia).
- •medications that affect cortical excitability, as determined by the investigator.
- •Have ever taken esketamine / ketamine for treatment of depression.
- •Are currently admitted or have ever been admitted to a dedicated psychiatric ward for depression for a period of more than 24 hours.
- •Have ever been diagnosed with obsessive-compulsive disorder (OCD) or bipolar type 1 or 2 disorder.
- •Be diagnosed with PTSD, agoraphobia, anorexia or bulimia, panic or personality disorder, with active symptoms, based on the investigator's judgment.
- •Have any history of myocardial infarction, coronary artery bypass graft (CABG), coronary heart failure (CHF), or history of other cardiac issues.
- •Be currently experiencing or have a history of intractable migraines.
- •Be a chronic nicotine user.
- •Be currently pregnant or breastfeeding or planning to become pregnant or breastfeed any time during the study, or lack a medically acceptable method of contraception in females with child-bearing potential.
- •Be currently incarcerated.
- •Be participating concurrently in another clinical investigation or have participated in a clinical investigation within the last 90 days or intend to participate in another clinical investigation during the study.
- •Have a hairstyle or hair type, such as very thick hair or voluminous hairstyle, that would prevent wearing of the treatment cap tightly enough on the head that the electrodes are held close to the scalp.
研究组 & 干预措施
Sham treatment
Sham Comparator
干预措施: Sham transcranial direct current stimulation (Device)
Active treatment
Experimental
干预措施: Transcranial direct current stimulation (Device)
结局指标
主要结局
MADRS: change from baseline
时间窗: 10 weeks from treatment initiation.
Mean change in depressive symptoms, measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score, from baseline to week 10. MADRS ranges from 0 to 60, with higher scores indicating more severe depression.
次要结局
- PHQ-9: change from baseline(10 weeks from treatment initiation.)
- PHQ-9: rate of response(10 weeks from treatment initiation.)
- PHQ-9: rate of remission(10 weeks from treatment initiation.)
- MADRS: rate of response(10 weeks from treatment initiation.)
- HAM-D17: rate of remission(10 weeks from treatment initiation.)
- CGI-I(10 weeks from treatment initiation.)
- MADRS: rate of response(10 weeks from treatment initiation.)
- HAM-D17: change form baseline(10 weeks from treatment initiation.)
- HAM-D17: rate of response(10 weeks from treatment initiation.)
- HAM-D17: rate of remission(10 weeks from treatment initiation.)
- PHQ-9: change from baseline(10 weeks from treatment initiation.)
- MADRS: rate of remission(10 weeks from treatment initiation.)
- PHQ-9: rate of response(10 weeks from treatment initiation.)
- PHQ-9: rate of remission(10 weeks from treatment initiation.)
- CGI-I(10 weeks from treatment initiation.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Safety and Feasibility of Tele-supervised Home-based Transcranial Direct Current Stimulation in Parkinson's DiseaseParkinson DiseaseNCT06804668Brigham and Women's Hospital6
已完成
不适用
Exercise Prehabilitation for Patients With NSCLC Before SurgeryPrehabilitationSurgeryNon Small Cell Lung CancerCardiorespiratory FitnessNCT05608759Tongji Hospital30
招募中
4 期
Effectiveness and Safety of At-home Gait Rehabilitation Using Wearable Exoskeletal RobotGait, SpasticGait, HemiplegicStrokeNCT06543758Yonsei University16
已完成
不适用
Remote Monitoring and Home-based Health Care for Treatment of Bone Marrow Transplant PatientsBone Marrow TransplantNCT05662631University of Colorado, Denver10
已完成
不适用
Feasibility of an at-home intervention to reduce prolonged sitting in patients hospitalised for an acute exacerbation of chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease (COPD)RespiratoryChronic obstructive pulmonary diseaseISRCTN13790881niversity Hospitals of Leicester NHS Trust (UK)60